Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT02153229 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Phase II Trial of Radical Pleurectomy With or Without Intraoperative PDT for Malignant Pleural Mesothelioma

Study acronym: MPM-PDT
StatusActive, Not Recruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗

Record History

  1. Primary completion date: Nov 11, 2024 to Dec 16, 2026 Completion date: Dec 2025 to Dec 2027v20 Show 1 more changeShow less
    • Completion date: Dec 2025 to Dec 2027
  2. Completion date: Jun 2025 to Dec 2025v19
  3. Trial status: Recruiting to Active, Not Recruiting Enrollment target: estimated 102 to confirmed 52 · Primary completion date changed from estimate of Dec 2024 to Nov 11, 2024 · Start date: May 2014 to Jun 2, 2014 · 1 morev18 Show 4 more changesShow less
    • Enrollment target: estimated 102 to confirmed 52
    • Primary completion date changed from estimate of Dec 2024 to Nov 11, 2024
    • Start date: May 2014 to Jun 2, 2014
    • Study sites revised (2)

    See this version in full on ClinicalTrials.gov ↗

  4. Primary completion date: May 2024 to Dec 2024 Completion date: Dec 2024 to Jun 2025v17 Show 1 more changeShow less
    • Completion date: Dec 2024 to Jun 2025
  5. Primary completion date: Jun 2023 to May 2024 Completion date: Dec 2023 to Dec 2024v16 Show 1 more changeShow less
    • Completion date: Dec 2023 to Dec 2024
Show 14 earlier versionsHide 14 earlier versions
  1. Primary completion date: Jun 2022 to Jun 2023 Completion date: Dec 2022 to Dec 2023v15 Show 1 more changeShow less
    • Completion date: Dec 2022 to Dec 2023
  2. Re-verified, no change to tracked fieldsv14
  3. Secondary endpoints expanded, about 8 wordsv13 See this version in full on ClinicalTrials.gov ↗
  4. Trial status: Suspended to Recruiting Primary completion date: Jul 2021 to Jun 2022 · Primary endpoint revised · Site details revised at 2 of 2 sitesv12 Show 3 more changesShow less
    • Primary completion date: Jul 2021 to Jun 2022
    • Primary endpoint revised
    • Site details revised at 2 of 2 sites

    See this version in full on ClinicalTrials.gov ↗

  5. Primary completion date: May 2020 to Jul 2021v11
  6. Trial status: Active, Not Recruiting to Suspended Sponsor's reason: Covid-19v10
  7. Trial status: Recruiting to Active, Not Recruiting Site details revised at 2 of 2 sitesv9 Show 1 more changeShow less
    • Site details revised at 2 of 2 sites
  8. Primary completion date: May 2018 to May 2020 Completion date: Dec 2022 · Study title expanded, about 10 wordsv8 Show 2 more changesShow less
    • Completion date: Dec 2022
    • Study title expanded, about 10 words

    See this version in full on ClinicalTrials.gov ↗

  9. Eligibility criteria expanded, about 9 words Site contacts updated at 1 of 2 sitesv7 Show 1 more changeShow less
    • Site contacts updated at 1 of 2 sites

    See this version in full on ClinicalTrials.gov ↗

  10. Re-verified, no change to tracked fieldsv6
  11. Completion date: May 2018 to not statedv5
  12. Site details revised at 1 of 2 sitesv4
  13. Re-verified, no change to tracked fieldsv3
  14. Enrollment target: 20 to 102v2
  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
A randomized Phase II trial to test whether the addition of intraoperative Photofrin-mediated photodynamic therapy to radical pleurectomy and post-operative chemo.improves OS in the treatment of patients with epithelioid MPM. Subjects assigned to the PDT arm will be given the photosensitizer prior to surgery . All subjects will receive maximal surgical debulking. Subjects in the PDT arm will receive intraoperative treatment using real-time, isotropic light dosimetry.
Trial Details
NCT Number NCT02153229
Lead Sponsor Abramson Cancer Center at Penn Medicine
Conditions Epitheliod Malignant Pleural Mesothelioma
Enrollment 52 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov